Company: IMNN
Filing Date: 2025-02-10
Form Type: 8-K
Source: 0001493152-25-005536
Chunk: 0

Company: Imunon, Inc.
Filing Date: 2025-02-10
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.

On
February 9, 2025, the Board of Directors of Imunon, Inc. (the “ Company”) appointed Dr. Douglas Faller (age 72) as Chief Medical
Officer.

Dr.
Faller, an internationally recognized oncologist/hematologist and scientist, has nearly 30 years of pharmaceutical and biotech industry
experience with a particular focus on clinical R& D, discovery, regulatory affairs, and strategy development. He has worked with small
molecules, gene therapies, biologics and cell therapies to address a range of malignant and non-malignant diseases and disorders, including
rare and genetic diseases, and neurological and neuropsychiatric disorders. He has extensive experience in early-stage development as
well as global late-stage development and world-wide marketing approvals. He has taken molecules (including those discovered in his own
academic laboratories) from first-in-human studies in the clinic, through registrational trials, international regulatory approvals and
commercial launch. Prior to his position with the Company, Dr. Faller served as Chief Medical Officer of Skyhawk Therapeutics beginning
in 2024, where he led the development of splicing modulators for the treatment of oncological and neurological disorders. From 2022 through
2024, he served as Chief Medical Officer of Oryzon Genomics, leading the development of epigenetic-modifying small molecules in oncology
and neuropsychiatric disorders, and prior to that role, from 2015 through 2022, Dr. Faller was Executive Medical Director at Takeda Pharmaceuticals,
where he led multiple programs in hematologic oncology, solid tumor malignancies and rare diseases, from first-in-human to global registrational
trials and post-marketing trials. He was also extensively involved in Business Development for oncology, hematology and rare diseases.
Dr. Faller was the scientific founder and CMO/CSO of Viracta Therapeutics, which he joined in 2019 and remained through 2021, after it
became publicly traded and launched a pivotal trial of his therapeutic. Dr. Faller is the scientific founder or co-founder of four biopharma
companies. Prior to working full-time in the biopharmaceutical industry, Dr. Faller was a professor at Harvard Medical School, and an
attending physician at Brigham